CVX
31
-9
VZ
39
-3
EQIX
45
-8
CCL
41
-13
MKC
48
-5
HCA
46
-4
JNJ
36
-3
GM
32
-14
HBI
43
-6
WYNN
14
-8
LRCX
42
-7
STX
28
4
DTE
25
-6
UNP
32
-4
HOG
31
-9
STI
5
-3
AMZN
45
-5
PSA
35
-3
RCL
55
-14
KR
59
3
CVX
31
-9
VZ
39
-3
EQIX
45
-8
CCL
41
-13
MKC
48
-5
HCA
46
-4
JNJ
36
-3
GM
32
-14
HBI
43
-6
WYNN
14
-8
LRCX
42
-7
STX
28
4
DTE
25
-6
UNP
32
-4
HOG
31
-9
STI
5
-3
AMZN
45
-5
PSA
35
-3
RCL
55
-14
KR
59
3
Financhill
Back

NovaBay Pharmaceuticals 10K Form

Sell
5

NBY
NovaBay Pharmaceuticals

Last Price:
$0.52
Seasonality Move:
-12.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBY News And Ratings

See the #1 stock for the next 7 days that we like better than NBY

NBY Financial Statistics

Sales & Book Value

Annual Sales: $9.8M
Cash Flow: $-2.1M
Price / Cash Flow: 0
Annual Sales: $0.22
Price / Book: 2.25

Profitability

EPS (TTM): -35.79620
Net Income (TTM): $-10.1M
Gross Margin: $6.5M
Return on Equity: -461.38%
Return on Assets: -144.37%

NovaBay Pharmaceuticals Earnings Forecast

Key NovaBay Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 22 years for NBY is 66.26%.
  • The Selling, General & Administrative Expenses for NBY have been equal to 116.69% of Gross Profit Margin.
  • The Research & Development expenses have been 0.43% of Revenue.
  • The Net Earning history of NBY is -73.85% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 12 years.

NovaBay Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NBY
CUSIP: 66987P
Website: novabay.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 1.15
Quick Ratio: 0.75

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NBY Technical Analysis vs Fundamental Analysis

Sell
5
NovaBay Pharmaceuticals (NBY) is a Sell

Is NovaBay Pharmaceuticals a Buy or a Sell?